Drl Generics-1 Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 1 Year 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16.00 Cr
About Drl Generics-1
Drl Generics-1 Private Limited (DGPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 June 2023 (One year and eight months 5 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹16.00 Cr.
Yogesh Bhandari, Bhawarlal, and Daksh Bhandari serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U46497KA2023PTC174573
-
Company No.
174573
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Jun 2023
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Who are the key members and board of directors at Drl Generics-1?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Bhandari
|
Director | 05-Jun-2023 | Current |
|
Bhawarlal
|
Director | 05-Jun-2023 | Current |
|
Daksh Bhandari
|
Director | 04-Aug-2023 | Current |
Financial Performance of Drl Generics-1.
Enhance accessibility to Drl Generics-1's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Drl Generics-1?
Unlock access to Drl Generics-1's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Idrs Labs Private LimitedYogesh Bhandari and . Bhawarlal are mutual person
-
Moksh Enterprises Private LimitedYogesh Bhandari is a mutual person
-
Mahaveer Medichem Private Limited
. Bhawarlal and Daksh Bhandari are mutual person
Charges (Loans)
₹160.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 16.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Dec 2023 | Hdfc Bank Limited | ₹16.00 Cr | Open |
How Many Employees Work at Drl Generics-1?
Unlock and access historical data on people associated with Drl Generics-1, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Drl Generics-1, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Drl Generics-1's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.